HUE058736T2 - Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére - Google Patents
Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezeléséreInfo
- Publication number
- HUE058736T2 HUE058736T2 HUE11810350A HUE11810350A HUE058736T2 HU E058736 T2 HUE058736 T2 HU E058736T2 HU E11810350 A HUE11810350 A HU E11810350A HU E11810350 A HUE11810350 A HU E11810350A HU E058736 T2 HUE058736 T2 HU E058736T2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- application methods
- amide derivatives
- mediated disorders
- cyclic amide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE058736T2 true HUE058736T2 (hu) | 2022-09-28 |
Family
ID=45497167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11810350A HUE058736T2 (hu) | 2010-07-20 | 2011-07-20 | Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20130274290A1 (enExample) |
| EP (2) | EP2595485B1 (enExample) |
| JP (3) | JP2013531073A (enExample) |
| KR (1) | KR101867634B1 (enExample) |
| CN (2) | CN107007603A (enExample) |
| BR (1) | BR112013001302A2 (enExample) |
| CA (2) | CA3154027A1 (enExample) |
| DK (1) | DK2595485T3 (enExample) |
| ES (1) | ES2914120T3 (enExample) |
| HU (1) | HUE058736T2 (enExample) |
| PL (1) | PL2595485T3 (enExample) |
| PT (1) | PT2595485T (enExample) |
| RU (2) | RU2746871C2 (enExample) |
| TW (1) | TWI520949B (enExample) |
| WO (1) | WO2012012543A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| WO2015191554A1 (en) * | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| CN107567444A (zh) | 2014-12-02 | 2018-01-09 | 田边三菱制药株式会社 | 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物 |
| CN109689055A (zh) * | 2016-05-25 | 2019-04-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| BR112019027398A2 (pt) | 2017-06-21 | 2020-07-07 | Minerva Neurosciences, Inc. | formas de dosagem orais de liberação controlada gastrorresistente |
| AU2019326525B2 (en) * | 2018-08-21 | 2025-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| IL298323B2 (en) | 2020-05-20 | 2023-10-01 | Univ Illinois | A method for treating lysosomal storage disease using histatin peptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2069318A1 (en) * | 1989-10-27 | 1991-04-28 | Engelbert Ciganek | (n-phthalimidoalkyl) piperidines |
| NZ235841A (en) * | 1989-10-27 | 1993-03-26 | Du Pont | (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions |
| WO1993022309A1 (en) * | 1992-04-23 | 1993-11-11 | Merrell Dow Pharmaceuticals Inc. | 4-imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy |
| AU2001234175B2 (en) * | 2000-02-29 | 2004-10-07 | Mitsubishi Pharma Corporation | Novel cyclic amide derivatives |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en not_active Ceased
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active Active
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en not_active Abandoned
-
2025
- 2025-01-15 US US19/021,774 patent/US20250228838A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| LT2558105T (lt) | Bardoksolono metilas, skirtas nutukimo gydymui | |
| EP2552433A4 (en) | COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES | |
| IL235275B (en) | 2,2-difluoropropionamide derivatives of methyl bardoxolone, their polymorphic forms and methods of using them | |
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| HUE061548T2 (hu) | Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| PT3412687T (pt) | Métodos de tratamento de dlbcl | |
| BRPI0813516A2 (pt) | Tratamento de distúrbios proliferativos de células b | |
| PL3133396T3 (pl) | Sposób leczenia z zastosowaniem leków wychwytujących amoniak | |
| PL2427193T3 (pl) | Zastosowanie inhibitorów pde7 do leczenia zaburzeń ruchu | |
| UA22037S (uk) | Пристрій для сексуальної стимуляції | |
| PL2437742T3 (pl) | Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń | |
| IL228030B (en) | Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| PL2768859T3 (pl) | Antagoniści IL17C do leczenia zaburzeń zapalnych | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| HUE058736T2 (hu) | Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére | |
| PL2718434T3 (pl) | Kompozycje i sposoby leczenia choroby trzewnej | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| PL2900230T3 (pl) | Związki do leczenia otyłości i sposoby ich zastosowania | |
| EP2635419A4 (en) | STRUCTURING OF NON-CONVEX SHAPED NANOSTRUCTURES | |
| PT2623499E (pt) | Derivado de 1,2,4-triazolona para tratamento de distúrbios de humor | |
| SMT201600395B (it) | Derivati di pantotenato per il trattamento di disturbi neurologici | |
| IL227747A0 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme |